Company continues to progress both REYOBIQ™ radiotherapeutic clinical trials and CNSide® CSF assay platform launch readiness ...

In the short term, it's possible that a company will deliver great business performance but still see its share price decline due to pressures shaping the stock market at large. However ...

Total Assets 3,722.66 2,905.32 2,100.19 1,559.30 ...

Total Liabilities 195.89 127.73 104.43 88.03 ...